Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncology (Williston Park, N.Y.)|May 10, 2011
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challengeRichard Kim, Michael T Byrne, Ann Tan, et al.
BMJ Case Reports|July 11, 2012
Postsplenectomy thromboembolic disease in congenital sideroblastic anaemiaMichael T Byrne, Anke K Bergman, Angela I Ruiz, et al.
Transplantation and Cellular Therapy|October 25, 2025
Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral BarriersMazyar Shadman, Sairah Ahmed, Michael T Byrne, et al.
American Journal of Hematology|March 9, 2026
Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid LeukemiaSomedeb Ball, Farrukh T Awan, Ben K Tomlinson, et al.
Ejhaem|March 12, 2021
New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamideBrendan L Mangan, Dilan Patel, Heidi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2022
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic SyndromesAsmita Mishra, Roni Tamari, Amy E DeZern, et al.
Haematologica|September 22, 2018
Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignanciesJocelyn S Gandelman, Michael T Byrne, Akshitkumar M Mistry, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 26, 2016
Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 SignalingRomany A N Johnpulle, Sophie Paczesny, Dae Kwang Jung, et al.
Blood Advances|January 17, 2024
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trialGail J Roboz, Guillermo Sanz, Elizabeth A Griffiths, et al.
Pageof 2